Literature DB >> 29733695

Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.

Sonia Gaur1, Stephanie Harmon2, Lauren Rosenblum1, Matthew D Greer1, Sherif Mehralivand3, Mehmet Coskun4, Maria J Merino1, Bradford J Wood5, Joanna H Shih6, Peter A Pinto3, Peter L Choyke1, Baris Turkbey1.   

Abstract

OBJECTIVE: The purposes of this study were to assess correlation of apparent diffusion coefficient (ADC) and normalized ADC (ratio of tumor to nontumor tissue) with the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) and updated International Society of Urological Pathology (ISUP) categories and to determine how to optimally use ADC metrics for objective assistance in categorizing lesions within PI-RADSv2 guidelines.
MATERIALS AND METHODS: In this retrospective study, 100 patients (median age, 62 years; range, 44-75 years; prostate-specific antigen level, 7.18 ng/mL; range, 1.70-84.56 ng/mL) underwent 3-T multiparametric MRI of the prostate with an endorectal coil. Mean ADC was extracted from ROIs based on subsequent prostatectomy specimens. Histopathologic analysis revealed 172 lesions (113 peripheral, 59 transition zone). Two radiologists blinded to histopathologic outcome assigned PI-RADSv2 categories. Kendall tau was used to correlate ADC metrics with PI-RADSv2 and ISUP categories. ROC curves were used to assess the utility of ADC metrics in differentiating each reader's PI-RADSv2 DWI category 4 or 5 assessment in the whole prostate and by zone.
RESULTS: ADC metrics negatively correlated with ISUP category in the whole prostate (ADC, τ = -0.21, p = 0.0002; normalized ADC, τ = -0.21, p = 0.0001). Moderate negative correlation was found in expert PI-RADSv2 DWI categories (ADC, τ = -0.34; normalized ADC, τ = -0.31; each p < 0.0001) maintained across zones. In the whole prostate, AUCs of ADC and normalized ADC were 87% and 82% for predicting expert PI-RADSv2 DWI category 4 or 5. A derived optimal cutoff ADC less than 1061 and normalized ADC less than 0.65 achieved positive predictive values of 83% and 84% for correct classification of PI-RADSv2 DWI category 4 or 5 by an expert reader. Consistent relations and predictive values were found by an independent novice reader.
CONCLUSION: ADC and normalized ADC inversely correlate with PI-RADSv2 and ISUP categories and can serve as quantitative metrics to assist with assigning PI-RADSv2 DWI category 4 or 5.

Entities:  

Keywords:  International Society of Urological Pathology; PI-RADS; apparent diffusion coefficient; multiparametric MRI; prostate

Mesh:

Substances:

Year:  2018        PMID: 29733695      PMCID: PMC7984719          DOI: 10.2214/AJR.17.18702

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  34 in total

1.  Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer.

Authors:  Edward M Lawrence; Ferdia A Gallagher; Tristan Barrett; Anne Y Warren; Andrew N Priest; Debra A Goldman; Deborah Goldman; Evis Sala; Vincent J Gnanapragasam
Journal:  AJR Am J Roentgenol       Date:  2014-09       Impact factor: 3.959

2.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

3.  Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look.

Authors:  Andrew B Rosenkrantz; Aytekin Oto; Baris Turkbey; Antonio C Westphalen
Journal:  AJR Am J Roentgenol       Date:  2016-02-25       Impact factor: 3.959

4.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

5.  Biological determinants of cancer progression in men with prostate cancer.

Authors:  T A Stamey; J E McNeal; C M Yemoto; B M Sigal; I M Johnstone
Journal:  JAMA       Date:  1999-04-21       Impact factor: 56.272

6.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

Authors:  Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2010-12-21       Impact factor: 11.105

7.  MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy.

Authors:  Oliver Ruprecht; Philipp Weisser; Boris Bodelle; Hanns Ackermann; Thomas J Vogl
Journal:  Eur J Radiol       Date:  2011-02-26       Impact factor: 3.528

8.  Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis.

Authors:  Kirema Garcia-Reyes; Niccolò M Passoni; Mark L Palmeri; Christopher R Kauffman; Kingshuk Roy Choudhury; Thomas J Polascik; Rajan T Gupta
Journal:  Abdom Imaging       Date:  2015-01

9.  Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation.

Authors:  Xi Zhen Wang; Bin Wang; Zhi Qin Gao; Jin Gang Liu; Zuo Qin Liu; Qing Liang Niu; Zhen Kui Sun; Yu Xiao Yuan
Journal:  J Magn Reson Imaging       Date:  2009-06       Impact factor: 4.813

10.  Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness.

Authors:  Andrei Lebovici; Silviu A Sfrangeu; Diana Feier; Cosmin Caraiani; Ciprian Lucan; Mihai Suciu; Florin Elec; Gheorghita Iacob; Mircea Buruian
Journal:  BMC Med Imaging       Date:  2014-05-10       Impact factor: 1.930

View more
  6 in total

1.  Biparametric prostate MRI: impact of a deep learning-based software and of quantitative ADC values on the inter-reader agreement of experienced and inexperienced readers.

Authors:  Stefano Cipollari; Martina Pecoraro; Alì Forookhi; Ludovica Laschena; Marco Bicchetti; Emanuele Messina; Sara Lucciola; Carlo Catalano; Valeria Panebianco
Journal:  Radiol Med       Date:  2022-09-17       Impact factor: 6.313

2.  Variability in contrast and apparent diffusion coefficient of kiwifruit used as prostate MRI phantom: 1-week validation.

Authors:  Tatsuya Hayashi; Shimpei Yano; Shinya Kojima; Toshimune Ito
Journal:  Radiol Phys Technol       Date:  2022-09-05

Review 3.  PI-RADSv2.1: Current status.

Authors:  Stephanie M Walker; Barış Türkbey
Journal:  Turk J Urol       Date:  2020-10-09

4.  Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.

Authors:  Antonio C Westphalen; Farhad Fazel; Hao Nguyen; Miguel Cabarrus; Katryana Hanley-Knutson; Katsuto Shinohara; Peter R Carroll
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

5.  The value of the apparent diffusion coefficient value in the Liver Imaging Reporting and Data System (LI-RADS) version 2018.

Authors:  Gehad Ahmad Saleh; Ahmed Abdel Khalek Abdel Razek; Lamiaa Galal El-Serougy; Walaa Shabana; Rihame Abd El-Wahab
Journal:  Pol J Radiol       Date:  2022-01-17

6.  Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.

Authors:  Riccardo Laudicella; Jan H Rüschoff; Niels J Rupp; Irene A Burger; Daniela A Ferraro; Muriel D Brada; Daniel Hausmann; Iliana Mebert; Alexander Maurer; Thomas Hermanns; Daniel Eberli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-18       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.